NewLimit
NewLimit develops epigenetic reprogramming medicines designed to restore function in aging cells and treat age-related disease.
$435MSeries C
ParticipantG
Greenoaks
Activity from announced rounds
Activity in this selectionOct 25, 2026 · Biotech · Jan 1, 2026
Greenoaks is an investment firm identified by AIR’s founder and by Medici Brands, whose announcement quotes partner Neil Shah.
Recorded funding activity
Medici builds consumer food brands across protein products and confectionery. AIR secures AI-agent workflows, while Airbound develops autonomous delivery aircraft. These companies have separate products and financing events despite similar company names.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $435M 1 disclosed · full round size, not this investor’s share